Intuitive Biosciences Inc.
Madison, WI
- UEI
- NTJMYEMGRKH1
- CAGE
- 9RJT5, 86NP9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 918 Deming Way #100, Madison, WI 53717, USA
- Website
- intuitivebio.com
- Founded
- 2012
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $306,206 |
Contract awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Northwestern University | U54EB027049 | $149,926 |
Similar vendors
About the company
Intuitive Biosciences Inc., a Madison, Wisconsin–based self-certified small disadvantaged business, develops point-of-care diagnostic assays for infectious disease detection and acts as a prime recipient on National Institutes of Health Small Business Innovation Research (SBIR) awards and as a sub-recipient on NIH grant work. The company operates as a for-profit manufacturer of goods, competing exclusively under small-business set-asides across its federal footprint.
Intuitive Biosciences' capability portfolio centers on lateral-flow immunoassay development for rapid, blood-based diagnostics. The company has executed two SBIR Phase I contracts with the National Institute of Allergy and Infectious Diseases (NIAID): a $306,206 award (Sep 2023–Aug 2024) to develop an EV-HIV assay using extracellular vesicles as diagnostic markers, and a prior $299,855 SBIR Phase I award (Jul 2022–Aug 2023) for related HIV detection research at the Madison facility. Both contracts carried Total Small Business set-aside designations. The company is also a sub-recipient on grant work through Northwestern University's Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases (C-THAN), awarded in March 2026.
Customer concentration is narrow and concentrated in health research funding. The National Institute of Allergy and Infectious Diseases accounts for both SBIR prime awards and 100% of the company's combined potential value ($606 thousand across three awards). The National Institute of Biomedical Imaging and Bioengineering represents the second customer. Activity is sparse — one award per year across 2022, 2023, and 2026 — with no federal contract vehicles or IDIQs present in the footprint. The company's federal engagement to date is confined to research-phase SBIR work and sub-recipient status on NIH grants, with no delivery orders, task orders, or prime grants beyond the SBIR program visible in the source data.
Quick answers
Is Intuitive Biosciences Inc. registered in SAM.gov?
Yes. Intuitive Biosciences Inc.'s SAM.gov registration is active through August 5, 2027.
How much has Intuitive Biosciences Inc. received in federal contracts?
Federal contracts obligated $306,206 to Intuitive Biosciences Inc. in fiscal years 2023 through 2027.
What is Intuitive Biosciences Inc.'s most recent federal award?
Intuitive Biosciences Inc.'s most recent federal contract award is "the EV-HIV assay, a point-of-care lateral flow immunoassay to accurately identify HIV infection from blood-based… (75N93023C00007), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2023.
On GovTribe
See Intuitive Biosciences Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors